Clinical Trial: Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma

U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT07454031) titled 'Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma' on March 02.

Brief Summary: To evaluate the safety and tolerability of intraperitoneal PX in combination with nab-paclitaxel in patients with peritoneal metastatic mucinous adenocarcinoma, and to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D).

Study Start Date: March 15

Study Type: INTERVENTIONAL

Condition: Peritoneal (Metastatic) Cancer

Intervention: DRUG: intraperitoneal PX in combination with nab-paclitaxel

intraperitoneal PX in combination with nab-paclitaxel in patient...